Pre-made Daxdilimab benchmark antibody ( Whole mAb, anti-LILRA4/ILT7 therapeutic antibody, Anti-CD85g Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Daxdilimab biosimilar, Whole mAb, Anti-LILRA4/ILT7 Antibody: Anti-CD85g therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Daxdilimab is a novel drug designed to target and bind to ILT7, which is a cell surface molecule specific to the pDC type of dendritic cells. It is currently being investigated against autoimmune diseases and COVID-19. and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-135-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Daxdilimab biosimilar, Whole mAb, Anti-LILRA4/ILT7 Antibody: Anti-CD85g therapeutic antibody
INN Name	Daxdilimab
Target	LILRA4
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	Viela Bio
Conditions Approved	na
Conditions Active	Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury
Conditions Discontinued	na
Development Tech	na